Indication: It is suitable for the treatment of acute lymphocytic leukemia (ALL), acute granulocytic leukemia, acute monocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, melanoma, etc. This product has an inhibitory effect on the proliferation of the above-mentioned tumor cells, and has the best effect on the induction remission of acute lymphoblastic leukemia in children. Sometimes it may also be effective for patients who relapse after remission with some commonly used chemotherapy drugs, but the remission period is short when used alone, and it is easy to produce drug resistance, so it is often used in combination with other chemotherapy drugs to improve the efficacy.

Indication: It is suitable for the treatment of acute lymphocytic leukemia (ALL), acute granulocytic leukemia, acute monocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, melanoma, etc. This product has an inhibitory effect on the proliferation of the above-mentioned tumor cells, and has the best effect on the induction remission of acute lymphoblastic leukemia in children. Sometimes it may also be effective for patients who relapse after remission with some commonly used chemotherapy drugs, but the remission period is short when used alone, and it is easy to produce drug resistance, so it is often used in combination with other chemotherapy drugs to improve the efficacy.

Indication: It is suitable for the treatment of acute lymphocytic leukemia (ALL), acute granulocytic leukemia, acute monocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, melanoma, etc. This product has an inhibitory effect on the proliferation of the above-mentioned tumor cells, and has the best effect on the induction remission of acute lymphoblastic leukemia in children. Sometimes it may also be effective for patients who relapse after remission with some commonly used chemotherapy drugs, but the remission period is short when used alone, and it is easy to produce drug resistance, so it is often used in combination with other chemotherapy drugs to improve the efficacy.

Indication: Mercaptopurine tablets are a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. 1 Mercaptopurine tablets are indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Indication: Methotrexate tablets are dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen (1. 1) Treatment of adults with mycosis fungoides (1. 1) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen (1. 1) Treatment of adults with rheumatoid arthritis (1. 2) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) (1. 3) Treatment of adults with severe psoriasis (1. 4) Methotrexate tablets treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen treatment of adults with mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen. treatment of adults with relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen Methotrexate tablets Methotrexate tablets Methotrexate tablets.

Indication: Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: 1. 1 Cyclophosphamide is indicated for the treatment of: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.

Indication: Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1. 1 Treatment of adults with mycosis fungoides ( 1. 1 Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1. 1 Treatment of adults with rheumatoid arthritis ( 1. 2 Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1. 3 Treatment of adults with severe psoriasis ( 1. 4 Methotrexate tablets areindicated for the: treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) aspart of a combination chemotherapy maintenance regimen treatment of adults with mycosis fungoides (cutaneous T-cell lymphoma) as a single agent oras part of a combination chemotherapy regimen. treatment of adults with relapsed or refractory non-Hodgkin lymphomas as part ofa metronomic combination chemotherapy regimen Methotrexate tablets are indicated for the treatment ofadults with rheumatoid arthritis. Methotrexate tablets are indicated for the treatment ofpediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). Methotrexate tablets are indicated forthe treatment of adults with severe psoriasis.

Indication: Methotrexate Injection is a dihydrofolate reductase inhibitor indicated for the treatment of: adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen ( 1. 1 adults with relapsed or refractory non-Hodgkin lymphoma as part of a combination chemotherapy regimen ( 1. 2 adults and pediatric patients with Burkitt lymphoma as part of a combination chemotherapy regimen ( 1. 3 adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen ( 1. 4 Limitations of Use: 1. 5 Methotrexate Injection is indicated for the treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with Burkitt lymphoma as part of a combination chemotherapy regimen. Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. Methotrexate Injection is not indicated for non-oncology diseases.

Indication: Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases 1. 1 Minimal Change Nephrotic Syndrome in Pediatric Patients 1. 2 Limitations of Use: Cyclophosphamide Capsules are indicated for the treatment of: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Capsules, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide Capsules are indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use:.

Indication: Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases 1. 1 Minimal Change Nephrotic Syndrome in Pediatric Patients 1. 2 Limitations of Use: Cyclophosphamide Capsules are indicated for the treatment of: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Capsules, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. Cyclophosphamide Capsules are indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use:.